This review summarizes the clinical and molecular characteristics of genetic entities with aberrant HOXA/B/MEIS1, agents targeting the menin-KMT2A interaction and other molecular vulnerabilities in assembly of protein complexes or general transcription machinery as well as implications of these evolving therapies in childhood AML. This evidence concerns the gene MEIS1 and acute myeloid leukemia.